Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of “Moderate Buy” from Analysts

Immix Biopharma, Inc. (NASDAQ:IMMX) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $21.2857.

A number of research firms have issued reports on IMMX. HC Wainwright raised their target price on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Bank of America assumed coverage on Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating and a $27.00 price target on the stock. Lifesci Capital started coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price objective for the company. Morgan Stanley decreased their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th.

Institutional Trading of Immix Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of IMMX. California State Teachers Retirement System bought a new stake in Immix Biopharma during the 2nd quarter valued at about $566,000. Compass Financial Management LLC bought a new stake in shares of Immix Biopharma during the 2nd quarter valued at about $62,000. Velan Capital Investment Management LP grew its position in shares of Immix Biopharma by 46.6% during the 2nd quarter. Velan Capital Investment Management LP now owns 1,085,000 shares of the company’s stock valued at $11,186,000 after acquiring an additional 345,000 shares during the period. Wellington Management Group LLP bought a new stake in Immix Biopharma during the second quarter valued at about $15,191,000. Finally, United Capital Financial Advisors LLC bought a new position in shares of Immix Biopharma during the 2nd quarter valued at approximately $729,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Price Performance

IMMX stock opened at $13.94 on Monday. The stock has a market capitalization of $997.25 million, a PE ratio of -15.84 and a beta of 0.11. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $15.10. The company’s 50-day moving average is $10.62 and its 200-day moving average is $9.56.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, analysts anticipate that Immix Biopharma will post -0.74 earnings per share for the current fiscal year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.